Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Uveal Melanoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 606Cyclophosphamide 546Magnetic Resonance Spectroscopy 527Radiotherapy 514Specimen Handling 506Nivolumab 412Cisplatin 381Carboplatin 369Biopsy 306Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 270Standard of Care 267Drug Therapy 264fludarabine 263Dexamethasone 263Bevacizumab 253venetoclax 251Oxaliplatin 209Capecitabine 201Rituximab 199Radiation 192Fluorouracil 189Ipilimumab 188durvalumab 185Doxorubicin 179Etoposide 177atezolizumab 175

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Epilim × 1 year × Clear all
NCT02068586 2026-03-16

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Thomas Jefferson University

Phase 2 Active not recruiting
210 enrolled
Dermatologic

Uveal Melanoma

NCT06199557 2025-06-29

HUVAMER

Haukeland University Hospital

Phase 1/2 Recruiting
48 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡